Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 8,345,769 $ 7,842,667
Accounts receivable 10,034 82,305
Prepaid expenses and other current assets 273,262 338,049
Total Current Assets 8,629,065 8,263,021
Property and Equipment, net 308,210 359,592
Other Assets    
Restricted cash 2,292 101,171
In-process R&D 5,866,000
Goodwill 2,189,338
Deposits 69,798 69,798
Related party receivable 103,017
Total Other Assets 8,127,428 273,986
Total Assets 17,064,703 8,896,599
Current Liabilities    
Accounts payable 1,007,671 290,058
Deferred revenue 1,409,212
Accrued expenses and other liabilities 702,740 1,305,173
Total Current Liabilities 3,119,623 1,595,231
Long Term Liabilities    
Other long term liabilities 439,618 461,434
Deferred tax liability 2,111,760
Contingent consideration 2,385,000
Total Liabilities 8,056,001 2,056,665
Commitments and Contingencies  
Stockholders' Equity    
Common stock, $.0002 par value; 50,000,000 shares authorized, 35,769,846 and 26,204,390 shares issued and outstanding at June 30, 2017 (unaudited) and December 31, 2016, respectively 6,839 4,926
Additional paid-in capital 73,726,240 65,868,541
Accumulated deficit (63,413,508) (57,004,655)
Accumulated other comprehensive loss (148,266) (72,231)
Total Stockholders' Equity - Heat Biologics, Inc. 10,171,305 8,796,581
Non-Controlling Interest (1,162,603) (1,956,647)
Total Stockholders' Equity 9,008,702 6,839,934
Total Liabilities and Stockholders' Equity $ 17,064,703 $ 8,896,599